Recent advances in amyotrophic lateral sclerosis research: Perspectives for personalized clinical application

EPMA Journal

Volumn 1, Issue 2, 2010, Pages 343-361

  Benkler, Chen ^a   Offen, Daniel ^a   Melamed, Eldad ^a   Kupershmidt, Lana ^b   Amit, Tamar ^b   Mandel, Silvia ^b   Youdim, Moussa B H ^b   Weinreb, Orly ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Amyotrophic lateral sclerosis; Genetic manipulation; Iron chelating multifunctional drugs; Neurotrophic factors; Personalized medicine; Stem cells

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 5 [4 PROPARGYLPIPERAZINE 1 YLMETHYL] 8 HYDROXYCHOLINE; CILIARY NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; EPIGALLOCATECHIN GALLATE; FERRITIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE TRANSPORTER; HLA 20; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; LENTIVIRUS VECTOR; NEUROPROTECTIVE AGENT; PARVOVIRUS VECTOR; RASAGILINE; RILUZOLE; SOMATOMEDIN C; TETANUS TOXIN HEAVY CHAIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL RESEARCH; COMBINATION CHEMOTHERAPY; DNA MODIFICATION; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IRON BINDING CAPACITY; IRON CHELATION; IRON METABOLISM; LENTIVIRINAE; MACROGLIA; MOTONEURON; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NEURAL STEM CELL; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; VIRAL GENE DELIVERY SYSTEM;

EID: 79953034265     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0026-1     Document Type: Review

References (186)

1. Cronin S, Berger S, Ding J, Schymick JC, Washecka N, Hernandez DG, et al. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet. 2008; 17: 768-74.
2. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009; 4: 1-22.
3. Gonzalez de Aguilar JL, Echaniz-Laguna A, Fergani A, Rene F, Meininger V, Loeffler JP, et al. Amyotrophic lateral sclerosis: all roads lead to Rome. J Neurochem. 2007; 101: 1153-60.
4. Santillo AF, Skoglund L, Lindau M, Eeg-Olofsson KE, Tovi M, Engler H, et al. Frontotemporal dementia-amyotrophic lateral sclerosis complex is simulated by neurodegeneration with brain iron accumulation. Alzheimer Dis Assoc Disord. 2009; 23: 298-300.
5. Cozzolino M, Ferri A, Carri MT. Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid Redox Signal. 2008; 10: 405-43.
6. Valdmanis PN, Daoud H, Dion PA, Rouleau GA. Recent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep. 2009; 9: 198-205.
7. Strong MJ, Gordon PH. Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum? Amyotroph Lateral Scler Other Mot Neuron Disord. 2005; 6: 8-16.
8. Valdmanis PN, Rouleau GA. Genetics of familial amyotrophic lateral sclerosis. Neurology. 2008; 70: 144-52.
9. Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol. 2008; 85: 94-134.
10. Beghi E, Mennini T, Bendotti C, Bigini P, Logroscino G, Chio A, et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem. 2007; 14: 3185-200.
11. Brooks BR. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol. 2009; 65 Suppl 1: S17-23.
12. Pioro EP. Antioxidant therapy in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1 Suppl 4: 5-12; discussion 13-15.
13. Orrell RW, Lane RJ, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease. Cochrane Database Syst Rev; The Cochrane Collaboration; Published by JohnWiley & Sons, Ltd.; 2007. Issue 1.
14. van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. NeuroReport. 2002; 13: 1067-70.
15. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007; 6: 1045-53.
16. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev; The Cochrane Collaboration; Published by JohnWiley & Sons; 2007. Ltd. Issue 1.
17. Nefussy B, Drory VE. Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: novel developments and future directions in diagnosis, genetics, pathogenesis and therapies. EPMA-J. 2010. doi: 10. 1007/s13167-010-0027-0.
18. Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2007; 104: 2495-500.
19. Imon Y, Yamaguchi S, Yamamura Y, Tsuji S, Kajima T, Ito K, et al. Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases. J Neurol Sci. 1995; 134(Suppl): 27-32.
20. Oba H, Araki T, Ohtomo K, Monzawa S, Uchiyama G, Koizumi K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology. 1993; 189: 843-6.
21. Sutedja NA, Sinke RJ, van Vught PW, van der Linden MW, Wokke JH, van Duijn CM, et al. The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch Neurol. 2007; 64: 63-7.
22. Wang XS, Lee S, Simmons Z, Boyer P, Scott K, Liu W, et al. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci. 2004; 227: 27-33.
23. Danzeisen R, Achsel T, Bederke U, Cozzolino M, Crosio C, Ferri A, et al. Superoxide dismutase 1 modulates expression of transferrin receptor. J Biol Inorg Chem. 2006; 11: 489-98.
24. Mizuno Y, Amari M, Takatama M, Aizawa H, Mihara B, Okamoto K. Transferrin localizes in Bunina bodies in amyotrophic lateral sclerosis. Acta Neuropathol. 2006; 112: 597-603.
25. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci. 2004; 1012: 1-13.
26. Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P, David S. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci. 2009; 29: 610-9.
27. Wu AS, Kiaei M, Aguirre N, Crow JP, Calingasan NY, Browne SE, et al. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem. 2003; 85: 142-50.
28. Zheng H, Youdim MB, Weiner LM, Fridkin M. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem Pharmacol. 2005; 70: 1642-52.
29. Zheng H, Youdim MB, Weiner LM, Fridkin M. Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. J Pept Res. 2005; 66: 190-203.
30. Gal S, Zheng H, Fridkin M, Youdim MB. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res. 2010; 17: 15-27.
31. Gal S, Zheng H, Fridkin M, Youdim MB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem. 2005; 95: 79-88.
32. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem. 2005; 95: 68-78.
33. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhbitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem. 2007; 100: 490-502.
34. Avramovich-Tirosh Y, Bar-Am O, Amit T, Youdim MB, Weinreb O. Up-regulation of Hypoxia-Inducible Factor (HIF) -1alpha and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30. Curr Alzheimer Res. 2010; 7: 300-6.
35. Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, et al. Neurorescue Activity, APP Regulation and Amyloid-beta Peptide Reduction by Novel Multi-Functional Brain Permeable Iron- Chelating- Antioxidants, M-30 and Green Tea Polyphenol, EGCG. Curr Alzheimer Res. 2007; 4: 403-11.
36. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2009; 23: 3766-79.
37. Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration b. 2007.
38. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2002; 10: 268-78.
39. Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol. 2004; 251: 1080-4.
40. Youdim MB, Fridkin M, Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev. 2005; 126: 317-26.
41. Cassina P, Peluffo H, Pehar M, Martinez-Palma L, Ressia A, Beckman JS, et al. Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis. J Neurosci Res. 2002; 67: 21-9.
42. Martin LJ. Transgenic mice with human mutant genes causing Parkinson's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. Rev Neurosci. 2007; 18: 115-36.
43. Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005; 19: 1899-901.
44. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MBH. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem. 2004; 89: 1119-25.
45. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004; 18: 1471-3.
46. Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MB. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal. 2010; 13: doi: 10. 1089/ars2009. 2929.
47. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, et al. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system J Biol Chem. 2005; 280: 41732-43.
48. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol. 2000; 59: 47-53.
49. Semenza GL, Agani F, Feldser D, Iyer N, Kotch L, Laughner E, et al. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol. 2000; 475: 123-30.
50. Almli LM, Hamrick SE, Koshy AA, Tauber MG, Ferriero DM. Multiple pathways of neuroprotection against oxidative stress and excitotoxic injury in immature primary hippocampal neurons. Brain Res Dev Brain Res. 2001; 132: 121-9.
51. Tolosa L, Mir M, Olmos G, Llado J. Vascular endothelial growth factor protects motoneurons from serum deprivation-induced cell death through phosphatidylinositol 3-kinase-mediated p38 mitogen-activated protein kinase inhibition. Neuroscience. 2009; 158: 1348-55.
52. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003; 34: 383-94.
53. Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destee A, et al. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J Neurol Neurosurg Psychiatry. 2006; 77: 255-7.
54. van Den Bosch L, Storkebaum E, Vleminckx V, Moons L, Vanopdenbosch L, Scheveneels W, et al. Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol Dis. 2004; 17: 21-8.
55. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 2001; 276: 9519-25.
56. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994; 269: 23757-63.
57. Brand K. Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr. 1997; 29: 355-64.
58. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res. 2001; 61: 7349-55.
59. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001; 12: 363-9.
60. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 2007; 64: 1930-44.
61. Kulp KS, Green SL, Vulliet PR. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp Cell Res. 1996; 229: 60-8.
62. Nurtjahja-Tjendraputra E, Fu D, Phang JM, Richardson DR. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood. 2007; 109: 4045-54.
63. Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J. 2008; 22: 1296-305.
64. Buck CR, Seburn KL, Cope TC. Neurotrophin expression by spinal motoneurons in adult and developing rats. J Comp Neurol. 2000; 416: 309-18.
65. Namiki J, Kojima A, Tator CH. Effect of brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 on functional recovery and regeneration after spinal cord injury in adult rats. J Neurotrauma. 2000; 17: 1219-31.
66. Qin DX, Zou XL, Luo W, Zhang W, Zhang HT, Li XL, et al. Expression of some neurotrophins in the spinal motoneurons after cord hemisection in adult rats. Neurosci Lett. 2006; 410: 222-7.
67. Bendotti C, Carri MT. Lessons from models of SOD1-linked familial ALS. Trends Mol Med. 2004; 10: 393-400.
68. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006; 351: 602-11.
69. Sumi H, Kato S, Mochimaru Y, Fujimura H, Etoh M, Sakoda S. Nuclear TAR DNA binding protein 43 expression in spinal cord neurons correlates with the clinical course in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2009; 68: 37-47.
70. Weinreb O, Amit T, Mandel S, Youdim MB. Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr. 2009; 4: 283-96.
71. Koh SH, Kwon H, Kim KS, Kim J, Kim MH, Yu HJ, et al. Epigallocatechin gallate prevents oxidative-stress-induced death of mutant Cu/Zn-superoxide dismutase (G93A) motoneuron cells by alteration of cell survival and death signals. Toxicology. 2004; 202: 213-25.
72. Koh SH, Lee SM, Kim HY, Lee KY, Lee YJ, Kim HT, et al. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci Lett. 2006; 395: 103-7.
73. Xu Z, Chen S, Li X, Luo G, Li L, Le W. Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochem Res. 2006; 31: 1263-9.
74. Beck M, Flachenecker P, Magnus T, Giess R, Reiners K, Toyka KV, et al. Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. Amyotroph Lateral Scler Other Mot Neuron Disord. 2005; 6: 100-3.
75. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000; 1: 201-6.
76. The BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology. 1999; 52: 1427-33.
77. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology. 1998; 51: 583-6.
78. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology. 1997; 49: 1621-30.
79. Nagano I, Shiote M, Murakami T, Kamada H, Hamakawa Y, Matsubara E, et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res. 2005; 27: 768-72.
80. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology. 1996; 46: 1244-9.
81. Miller RG, Bryan WW, Dietz MA, Munsat TL, Petajan JH, Smith SA, et al. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology. 1996; 47: 1329-31.
82. Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol. 1996; 39: 256-60.
83. Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. Exp Neurol. 2009; 223: 229-37.
84. Mazzini L, Mareschi K, Ferrero I, Vassallo E, Oliveri G, Nasuelli N, et al. Stem cell treatment in Amyotrophic Lateral Sclerosis. J Neurol Sci. 2008; 265: 78-83.
85. Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008; 71: 1326-34.
86. Aebischer P, Pochon NA, Heyd B, Deglon N, Joseph JM, Zurn AD, et al. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther. 1996; 7: 851-60.
87. Aebischer P, Schluep M, Déglon N, Joseph JM, Hirt L, Heyd B, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med. 1996; 2: 696-9.
88. Zurn AD, Henry H, Schluep M, Aubert V, Winkel L, Eilers B, et al. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transplant. 2000; 9: 471-84.
89. Dodge JC, Haidet AM, Yang W, Passini MA, Hester M, Clarke J, et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther. 2008; 16: 1056-64.
90. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003; 301: 839-42.
91. Franz CK, Federici T, Yang J, Backus C, Oh SS, Teng Q, et al. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis. 2009; 33: 473-81.
92. Lepore AC, Haenggeli C, Gasmi M, Bishop KM, Bartus RT, Maragakis NJ, et al. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007; 1185: 256-65.
93. Wang LJ, Lu YY, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci. 2002; 22: 6920-8.
94. Azzouz M, Hottinger A, Paterna JC, Zurn AD, Aebischer P, Büeler H. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum Mol Genet. 2000; 9: 803-11.
95. Guillot S, Azzouz M, Déglon N, Zurn A, Aebischer P. Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice. Neurobiol Dis. 2004; 16: 139-49.
96. Hottinger AF, Azzouz M, Déglon N, Aebischer P, Zurn AD. Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci. 2000; 20: 5587-93.
97. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004; 429: 413-7.
98. Moreno-Igoa M, Calvo AC, Penas C, Manzano R, Oliván S, Muñoz MJ, et al. Fragment C of tetanus toxin, more than a carrier. Novel perspectives in non-viral ALS gene therapy. J Mol Med. 2010; 88: 297-308.
99. Chian RJ, Li J, Ay I, Celia SA, Kashi BB, Tamrazian E, et al. IGF-1: tetanus toxin fragment C fusion protein improves delivery of IGF-1 to spinal cord but fails to prolong survival of ALS mice. Brain Res. 2009; 1287: 1-19.
100. Ciriza J, Moreno-Igoa M, Calvo AC, Yague G, Palacio J, Miana-Mena FJ, et al. A genetic fusion GDNF-C fragment of tetanus toxin prolongs survival in a symptomatic mouse ALS model. Restor Neurol Neurosci. 2008; 26: 459-65.
101. Xu L, Ryugo DK, Pongstaporn T, Johe K, Koliatsos VE. Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J Comp Neurol. 2009; 514: 297-309.
102. Xu L, Yan J, Chen D, Welsh AM, Hazel T, Johe K, et al. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation. 2006; 82: 865-75.
103. Lepore AC, Rauck B, Dejea C, Pardo AC, Rao MS, Rothstein JD, et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci. 2008; 11: 1294-301.
104. Maragakis NJ, Rao MS, Llado J, Wong V, Xue H, Pardo A, et al. Glial restricted precursors protect against chronic glutamate neurotoxicity of motor neurons in vitro. Glia. 2005; 50: 145-59.
105. Boucherie C, Schäfer S, Lavand'homme P, Maloteaux JM, Hermans E. Chimerization of astroglial population in the lumbar spinal cord after mesenchymal stem cell transplantation prolongs survival in a rat model of amyotrophic lateral sclerosis. J Neurosci Res. 2009; 87: 2034-46.
106. Kim H, Kim HY, Choi MR, Hwang S, Nam KH, Kim HC, et al. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. Neurosci Lett. 2010; 468: 190-4.
107. Vercelli A, Mereuta OM, Garbossa D, Muraca G, Mareschi K, Rustichelli D, et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2008; 31: 395-405.
108. Zhao CP, Zhang C, Zhou SN, Xie YM, Wang YH, Huang H, et al. Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. Cytotherapy. 2007; 9: 414-26.
109. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, et al. Wild-type microglia extend survival in PU. 1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2006; 103: 16021-6.
110. Ohnishi S, Ito H, Suzuki Y, Adachi Y, Wate R, Zhang J, et al. Intra-bone marrow-bone marrow transplantation slows disease progression and prolongs survival in G93A mutant SOD1 transgenic mice, an animal model mouse for amyotrophic lateral sclerosis. Brain Res. 2009; 1296: 216-24.
111. Ende N, Weinstein F, Chen R, Ende M. Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). Life Sci. 2000; 67: 53-9.
112. Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M, et al. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther. 2005; 16: 509-21.
113. Park S, Kim HT, Yun S, Kim IS, Lee J, Lee IS, et al. Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. Exp Mol Med. 2009; 41: 487-500.
114. Suzuki M, McHugh J, Tork C, Shelley B, Klein SM, Aebischer P, et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE. 2007; 2: e689.
115. Suzuki M, McHugh J, Tork C, Shelley B, Hayes A, Bellantuono I, et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther. 2008; 16: 2002-10.
116. Hwang DH, Lee HJ, Park IH, Seok JI, Kim BG, Joo IS, et al. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther. 2009; 16: 1234-44.
117. Alisky JM, Davidson BL. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases. Hum Gene Ther. 2000; 11: 2315-29.
118. Berns KI. Parvovirus replication. Microbiol Rev. 1990; 54: 316-29.
119. Lu YY, Wang LJ, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T, et al. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport. Neurosci Res. 2003; 45: 33-40.
120. Cockrell AS, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol. 2007; 36: 184-204.
121. Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 1992; 11: 3053-8.
122. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996; 272: 263-7.
123. Azzouz M. Gene Therapy for ALS: progress and prospects. Biochim Biophys Acta. 2006; 1762: 1122-7.
124. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther. 2005; 5: 387-98.
125. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008; 321: 1218-21.
126. Harper JM, Krishnan C, Darman JS, Deshpande DM, Peck S, Shats I, et al. Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc Natl Acad Sci U S A. 2004; 101: 7123-8.
127. López-González R, Kunckles P, Velasco I. Transient recovery in a rat model of familial amyotrophic lateral sclerosis after transplantation of motor neurons derived from mouse embryonic stem cells. Cell Transplant. 2009; 18: 1171-81.
128. Garbuzova-Davis S, Willing AE, Milliken M, Saporta S, Zigova T, Cahill DW, et al. Positive effect of transplantation of hNT neurons (NTera 2/D1 cell-line) in a model of familial amyotrophic lateral sclerosis. Exp Neurol. 2002; 174: 169-80.
129. Willing AE, Garbuzova-Davis S, Saporta S, Milliken M, Cahill DW, Sanberg PR. hNT neurons delay onset of motor deficits in a model of amyotrophic lateral sclerosis. Brain Res Bull. 2001; 56: 525-30.
130. Sharma HS. Interaction between amino acid neurotransmitters and opioid receptors in hyperthermia-induced brain pathology. Prog Brain Res. 2007; 162: 295-317.
131. Luo Y, Xue H, Pardo AC, Mattson MP, Rao MS, Maragakis NJ. Impaired SDF1/CXCR4 signaling in glial progenitors derived from SOD1(G93A) mice. J Neurosci Res. 2007; 85: 2422-32.
132. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007; 10: 615-22.
133. Pramatarova A, Laganière J, Roussel J, Brisebois K, Rouleau GA. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci. 2001; 21: 3369-74.
134. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008; 11: 251-3.
135. Maragakis NJ, Rothstein JD. Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol. 2006; 2: 679-89.
136. Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, et al. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease. J Mol Neurosci. 2009; 39: 199-210.
137. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol. 2000; 164: 247-56.
138. Suzuki H, Taguchi T, Tanaka H, Kataoka H, Li Z, Muramatsu K, et al. Neurospheres induced from bone marrow stromal cells are multipotent for differentiation into neuron, astrocyte, and oligodendrocyte phenotypes. Biochem Biophys Res Commun. 2004; 322: 918-22.
139. François S, Bensidhoum M, Mouiseddine M, Mazurier C, Allenet B, Semont A, et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells. 2006; 24: 1020-9.
140. Battiwalla M, Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy. 2009; 11: 503-15.
141. Bossolasco P, Cova L, Calzarossa C, Servida F, Mencacci NE, Onida F, et al. Metalloproteinase alterations in the bone marrow of ALS patients. J Mol Med. 2010. doi: 10. 1007/s00109-009-0584-7.
142. Cho GW, Noh MY, Kim HY, Koh SH, Kim KS, Kim SH. Bone marrow derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity. Stem Cells Dev. 2009. doi: 10. 1089/scd. 2009. 0453.
143. Demestre M, Pullen A, Orrell RW, Orth M. ALS-IgG-induced selective motor neurone apoptosis in rat mixed primary spinal cord cultures. J Neurochem. 2005; 94: 268-75.
144. Engelhardt JI, Soós J, Obál I, Vigh L, Siklós L. Subcellular localization of IgG from the sera of ALS patients in the nervous system. Acta Neurol Scand. 2005; 112: 126-33.
145. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998; 23: 249-56.
146. Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol. 2009; 4: 389-98.
147. Sargsyan SA, Monk PN, Shaw PJ. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia. 2005; 51: 241-53.
148. Obál I, Jakab JS, Siklós L, Engelhardt JI. Recruitment of activated microglia cells in the spinal cord of mice by ALS IgG. NeuroReport. 2001; 12: 2449-52.
149. Pullen AH, Demestre M, Howard RS, Orrell RW. Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca2+ enhancement. Acta Neuropathol. 2004; 107: 35-46.
150. de Hemptinne I, Vermeiren C, Maloteaux JM, Hermans E. Induction of glial glutamate transporters in adult mesenchymal stem cells. J Neurochem. 2004; 91: 155-66.
151. Pineda JR, Rubio N, Akerud P, Urbán N, Badimon L, Arenas E, et al. Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells. Gene Ther. 2007; 14: 118-28.
152. Cunningham LA, Su C. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp Neurol. 2002; 174: 230-42.
153. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol. 2005; 57: 298-302.
154. Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg. 2007; 106: 614-20.
155. Li W, Brakefield D, Pan Y, Hunter D, Myckatyn TM, Parsadanian A. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp Neurol. 2007; 203: 457-71.
156. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001; 28: 131-8.
157. Wang Y, Mao XO, Xie L, Banwait S, Marti HH, Greenberg DA, et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci. 2007; 27: 304-7.
158. Lambrechts D, Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta. 2006; 1762: 1109-21.
159. Rizvanov AA, Kiyasov AP, Gaziziov IM, Yilmaz TS, Kaligin MS, Andreeva DI, et al. Human umbilical cord blood cells transfected with VEGF and L(1)CAM do not differentiate into neurons but transform into vascular endothelial cells and secrete neuro-trophic factors to support neuro-genesis-a novel approach in stem cell therapy. Neurochem Int. 2008; 53: 389-94.
160. Zheng C, Nennesmo I, Fadeel B, Henter JI. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2004; 56: 564-7.
161. Bogaert E, van Damme P, Poesen K, Dhondt J, Hersmus N, Kiraly D, et al. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol Aging. 2009. doi: 10. 1016/j. neurobiolaging. 2008. 12. 007.
162. Tolosa L, Mir M, Asensio VJ, Olmos G, Lladó J. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J Neurochem. 2008; 105: 1080-90.
163. Vergani L, Finco C, Di Giulio AM, Muller EE, Gorio A. Effects of low doses of glycosaminoglycans and insulin-like growth factor-I on motor neuron disease in wobbler mouse. Neurosci Lett. 1997; 228: 41-4.
164. Vergani L, Losa M, Lesma E, Di Giulio AM, Torsello A, Muller EE, et al. Glycosaminoglycans boost insulin-like growth factor-I-promoted neuroprotection: blockade of motor neuron death in the wobbler mouse. Neuroscience. 1999; 93: 565-72.
165. Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008; 71: 1770-5.
166. Danbolt NC, Chaudhry FA, Dehnes Y, Lehre KP, Levy LM, Ullensvang K, et al. Properties and localization of glutamate transporters. Prog Brain Res. 1998; 116: 23-43.
167. Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001; 65: 1-105.
168. Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Arch Neurol. 2001; 58: 365-70.
169. Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci. 2008; 1144: 97-112.
170. Molz S, Decker H, Dal-Cim T, Cremonez C, Cordova FM, Leal RB, et al. Glutamate-induced toxicity in hippocampal slices involves apoptotic features and p38 MAPK signaling. Neurochem Res. 2008; 33: 27-36.
171. Lee Y, Park HW, Park SG, Cho S, Myung PK, Park BC, et al. Proteomic analysis of glutamate-induced toxicity in HT22 cells. Proteomics. 2007; 7: 185-93.
172. Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int. 2007; 51: 333-55.
173. Sonnewald U, Qu H, Aschner M. Pharmacology and toxicology of astrocyte-neuron glutamate transport and cycling. J Pharmacol Exp Ther. 2002; 301: 1-6.
174. Bendotti C, Tortarolo M, Suchak SK, Calvaresi N, Carvelli L, Bastone A, et al. Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem. 2001; 79: 737-46.
175. Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A. 2002; 99: 1604-9.
176. Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998; 20: 589-602.
177. Meyer T, Fromm A, Münch C, Schwalenstöcker B, Fray AE, Ince PG, et al. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J Neurol Sci. 1999; 170: 45-50.
178. Rothstein JD, van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995; 38: 73-84.
179. Guo H, Lai L, Butchbach ME, Stockinger MP, Shan X, Bishop GA, et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet. 2003; 12: 2519-32.
180. Joseph D'Ercole A, Ye P. Expanding the mind: insulin-like growth factor I and brain development. Endocrinology. 2008; 149: 5958-62.
181. Lunn JS, Sakowski SA, Kim B, Rosenberg AA, Feldman EL. Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration. Dev Neurobiol. 2009; 69: 871-84.
182. Murphy M, Dutton R, Koblar S, Cheema S, Bartlett P. Cytokines which signal through the LIF receptor and their actions in the nervous system. Prog Neurobiol. 1997; 52: 355-78.
183. Pierce RC, Bari AA. The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Rev Neurosci. 2001; 12: 95-110.
184. Saarma M, Sariola H. Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF). Microsc Res Tech. 1999; 45: 292-302.
185. Schulte-Herbrüggen O, Braun A, Rochlitzer S, Jockers-Scherübl MC, Hellweg R. Neurotrophic factors-a tool for therapeutic strategies in neurological. neuropsychiatric and neuroimmunological diseases? Curr Med Chem. 2007; 14: 2318-29.
186. Sendtner M, Carroll P, Holtmann B, Hughes RA, Thoenen H. Ciliary neurotrophic factor. J Neurobiol. 1994; 25: 1436-53.